Research

Studies

DOVACC
A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent Ovarian Cancer. This randomized, open-label Phase II study investigates the use of the therapeutic cancer vaccine UV1 in combination with olaparib and durvalumab compared to olaparib as monotherapy and the olaparib-durvalumab combination in maintenance therapy after platinum-containing combination therapy in BRCAwt patients with recurrent ovarian cancer.

NPLUS

HELP-ER
Retrospective / prospective study on the development of the HELP-ER score (improved AGO score). The main objective of the HELP-ER study is to improve the AGO score for predicting resectability by adding the biomarker human epididymal protein 4 (HE4). It has already been shown that HE4 is the only independent predictive marker for surgical outcome besides ascites. HEALTH Database Retrospective study for a better understanding of real-world (RW) treatment patterns and clinical outcomes in newly diagnosed advanced OC patients.

MAMOC is a multicenter, randomized, placebo controlled, double blind study including BRCA negative patients with histologically confirmed, advanced (FIGO stage IIIA, IIIB, IIIC, or IV of the 2014 FIGO classification) high grade serous or high grade endometrioid (based on local histopathological findings) ovarian cancer, fallopian tube cancer, primary peritoneal cancer and clear cell carcinoma of the ovary in first line therapy.

MOSAIC

EUDARIO

EUROPA